DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado
Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, BrasilPublikationen in Zusammenarbeit mit Forschern von Pontifícia Universidade Católica do Rio Grande do Sul (6)
2024
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038
2022
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097
2020
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588
-
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
European Journal of Cancer, Vol. 138, pp. 202-211
2018
-
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma
New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290
-
The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma
Cancer Immunology Research, Vol. 6, Núm. 7, pp. 758-765